ArticleBiology letters2015
Refugia and the evolutionary epidemiology of drug resistance.
Article in Biology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Population-level mathematical modeling of antimicrobial resistance: a systematic review.BMC medicine · 2019Pooled it
- Evolution and spread of multiadapted pathogens in a spatially heterogeneous environment.Evolution letters · 2024Article
- Survey of Staphylococcus aureus carriage by free-living red deer (Cervus elaphus): Evidence of human and domestic animal lineages.Transboundary and emerging diseases · 2022Article
- Frontiers in effective control of problem parasites in beekeeping.International journal for parasitology. Parasites and wildlife · 2022Article
- Refugia and anthelmintic resistance: Concepts and challenges.International journal for parasitology. Drugs and drug resistance · 2019Review
- Managing the emergence of pathogen resistance via spatially targeted antimicrobial use.Evolutionary applications · 2018Article
- The evolution of antibiotic resistance in a structured host population.Journal of the Royal Society, Interface · 2018Article
- Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites.Evolutionary applications · 2018Review
- The emergence, maintenance, and demise of diversity in a spatially variable antibiotic regime.Evolution letters · 2018Article
- The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistantEvolutionary applications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance is a long-standing economic, veterinary and human health concern in human and animal populations. Efficacy of prophylactic drug treatments targeting a particular pathogen is often short-lived, as drug-resistant pathogens evolve and reach high frequency in a treated population. Methods to combat drug resistance are usually costly, including use of multiple drugs that are applied jointly or sequentially, or development of novel classes of drugs. Alternatively, there is growing interest in exploiting untreated host populations, refugia, for the management of drug resistance. Refugia do not experience selection for resistance, and serve as a reservoir for native, drug-susceptible pathogens. The force of infection from refugia may dilute the frequency of resistant pathogens in the treated population, potentially at an acceptable cost in terms of overall disease burden. We examine this concept using a simple mathematical model that captures the core mechanisms of transmission and selection common to many host-pathogen systems. We identify the roles of selection and gene flow in determining the utility of refugia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.